Search
Displaying 521–530 of 1145 results
-
ProQR’s Phase 2/3 Clinical Trial for LCA10 RNA Therapy Doesn’t Meet Endpoints
Research NewsThe emerging treatment had shown encouraging results in a Phase ½ clinical trial
-
AGTC Plans Further Clinical Development of Achromatopsia (CNGB3) Gene Therapy
Research NewsInterim results for pediatric patients with CNGB3 mutations were encouraging
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
Genentech-Roche Receives FDA Approval for Vabysmo for Treatment of Wet AMD and DME
Research NewsThis new treatment can reduce the frequency of injections into the eye
-
Kriya Therapeutics Licenses Emerging Foundation-Funded Dry AMD Gene Therapy
Research NewsThe Foundation Fighting Blindness is funding Bärb Rohrer, PhD, Medical University of South Carolina, to evaluate safety and efficacy of the gene therapy in a large animal model
-
Foundation News
Commitment to expand translational research acceleration program and fund career development award.
-
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Research NewsCompany seeks to out-license its retinal progenitor therapy to a partner
.png)
.png)
